Exhibit 5.1
Faegre Drinker Biddle & Reath LLP
2200 Wells Fargo Center 90 South Seventh Street
Minneapolis Minnesota 55402-3901
Phone +1 612 766 7000
Fax +1 612 766 1600
March 30, 2020
Wells Fargo & Company
420 Montgomery Street
San Francisco, California 94104
Ladies and Gentlemen:
We have acted as counsel for Wells Fargo & Company, a Delaware corporation (the “Company”), in connection with (i) the preparation of a Registration Statement onForm S-3, as amended, FileNo. 333-236148 (the “Registration Statement”) of the Company filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the proposed offer and sale from time to time of the securities referred to therein; (ii) Pricing Supplement No. 1 dated March 23, 2020 to the Prospectus Supplement dated February 26, 2020 (the “Prospectus Supplement”) and the Prospectus dated February 25, 2020 (the “Prospectus”), relating to the offer and sale by the Company under the Registration Statement of $3,500,000,000 aggregate principal amount of Medium-Term Notes, Series U, Senior RedeemableFixed-to-Floating Rate Notes due April 4, 2051; (iii) Pricing Supplement No. 2 dated March 23, 2020 to the Prospectus Supplement and the Prospectus, relating to the offer and sale by the Company under the Registration Statement of $2,500,000,000 aggregate principal amount of Medium-Term Notes, Series U, Senior RedeemableFixed-to-Floating Rate Notes due April 4, 2031; and (iv) Pricing Supplement No. 3 dated March 26, 2020 to the Prospectus Supplement and the Prospectus, relating to the offer and sale by the Company under the Registration Statement of $2,000,000,000 aggregate principal amount of Medium-Term Notes, Series U, Senior RedeemableFixed-to-Floating Rate Notes due April 4, 2051 (the Medium-Term Notes described in clauses (ii) – (iv) being herein referred to collectively as the “Notes”). The Notes are to be issued under the Indenture dated as of February 21, 2017 (the “Indenture”) entered into by the Company and Citibank, N.A., as trustee, and sold pursuant to a Terms Agreement dated March 23, 2020 (the “2051 Terms Agreement (March 23)”), a Terms Agreement dated March 23, 2020 (the “2031 Terms Agreement (March 23)”) or a Terms Agreement dated March 26, 2020 (the “2051 Terms Agreement (March 26)”), as applicable, among the Company and the Agents named therein.
We have examined such documents, records and instruments as we have deemed necessary or appropriate for the purposes of this opinion.
Based on the foregoing, we are of the opinion that the Notes have been duly authorized and, when duly executed by the Company, authenticated in accordance with the provisions of the